Provigil and Acetaminophen Interaction: What You Need to Know

How Modafinil Is Metabolized and Why It Matters

Modafinil is processed primarily through amide hydrolysis and secondarily through CYP-mediated oxidation in the liver. According to the FDA-approved Provigil prescribing information, modafinil is an inducer of CYP3A4 and CYP3A5, a moderate inhibitor of CYP2C19, and a weak inhibitor of CYP2C9. These enzyme interactions set the stage for nearly every clinically relevant drug-drug interaction modafinil creates.

CYP3A4 Induction

CYP3A4 induction means that modafinil causes the body to produce more CYP3A4 enzyme over time. Drugs that rely on CYP3A4 for their primary clearance get metabolized faster, sometimes reducing their effectiveness. The induction effect is not immediate. It builds over approximately 7 to 14 days of continuous dosing, which is why short single-dose exposures carry less interaction risk than chronic daily use.

CYP2C9 Inhibition

Modafinil weakly inhibits CYP2C9. This slows the breakdown of CYP2C9 substrates, potentially raising their plasma concentrations. Acetaminophen is a minor CYP2C9 substrate, so this pathway contributes only modestly to the overall interaction picture, but it is worth tracking in high-dose scenarios.

Modafinil's Hepatic Half-Life

The terminal half-life of modafinil is approximately 15 hours in adults with normal liver function. In patients with severe hepatic impairment, the FDA label specifies that the dose should be reduced by 50% because clearance falls dramatically. This same impaired liver is one that also struggles to safely process acetaminophen's reactive metabolite, NAPQI.

How Acetaminophen Is Metabolized and Where the Overlap Begins

Acetaminophen undergoes three parallel hepatic routes: glucuronidation (approximately 55%), sulfation (approximately 30%), and CYP-mediated oxidation (approximately 5 to 15%) primarily through CYP2E1 and to a lesser extent CYP3A4. The CYP3A4 branch is particularly important here.

The NAPQI Problem

CYP3A4 converts acetaminophen into N-acetyl-p-benzoquinone imine, commonly abbreviated NAPQI. NAPQI is highly reactive and hepatotoxic. Under normal conditions, glutathione rapidly conjugates NAPQI and neutralizes it. The National Institutes of Health LiverTox database notes that hepatotoxicity occurs when NAPQI production outpaces glutathione supply, which can happen with overdose, malnutrition (low glutathione stores), or CYP induction by co-administered drugs.

Where Modafinil Increases Risk

Because modafinil induces CYP3A4, it could increase the proportion of acetaminophen that gets shunted through the CYP3A4 pathway. More CYP3A4 activity means more NAPQI per given acetaminophen dose. This mechanism is analogous to the well-documented interaction between rifampin (a potent CYP3A4 inducer) and acetaminophen, where Chun et al. (2012) in Drug Metabolism and Disposition demonstrated that rifampin pretreatment significantly elevated NAPQI formation markers. Modafinil is a far weaker inducer than rifampin, so the magnitude of effect is smaller, but the direction of the risk is the same.

Clinical Severity: How Dangerous Is This Combination?

Standard interaction databases, including Lexicomp and Drugs.com, classify the modafinil-acetaminophen interaction as minor to moderate, requiring monitoring rather than avoidance. That classification holds for healthy adults using both drugs at approved doses for short periods.

Scenarios Where Risk Escalates

The risk profile changes in specific circumstances:

Chronic daily use. A patient taking 200 mg modafinil every morning for shift-work sleep disorder while also relying on acetaminophen daily for chronic pain is being exposed to persistent CYP3A4 induction alongside a steady NAPQI load.

Pre-existing liver disease. Patients with even mild hepatic fibrosis have reduced glutathione synthesis and slower phase II conjugation. The American Association for the Study of Liver Diseases (AASLD) guidance on drug-induced liver injury emphasizes that baseline hepatic reserve is the single most important predictor of acetaminophen toxicity at sub-overdose doses.

Alcohol use. Alcohol induces CYP2E1, which is actually the dominant CYP enzyme for NAPQI production. Modafinil-related CYP3A4 induction stacks on top of CYP2E1 induction from alcohol. The FDA Drug Safety Communication on acetaminophen and alcohol warns patients consuming three or more alcoholic drinks daily to ask a healthcare provider before using any acetaminophen product.

Malnutrition and low body weight. Glutathione synthesis depends on cysteine and glycine availability. Patients who are malnourished have depleted glutathione stores. A smaller NAPQI load can overwhelm a compromised detoxification system.

Quantifying the Effect

No published pharmacokinetic trial has specifically studied modafinil plus acetaminophen as a primary endpoint. The mechanistic risk is extrapolated from:

1. Modafinil's known CYP3A4 induction potency (confirmed in the FDA label).
2. Studies showing that CYP3A4 contributes up to 15% of NAPQI generation, as summarized by Court et al. In Drug Metabolism and Disposition (2001).
3. Analog-drug induction studies (rifampin, carbamazepine) demonstrating that CYP3A4 inducers measurably increase NAPQI markers.

The absence of a head-to-head trial is itself clinically informative. Because the interaction is mechanistically plausible but quantitatively modest under standard conditions, it has not met the threshold for a dedicated safety study. That does not mean it can be ignored in high-risk populations.

Modafinil's Full CYP Profile and Other Acetaminophen Pathways

Understanding the full picture requires looking at both drugs' enzyme footprints side by side.

Modafinil as an Enzyme Modifier

| CYP Enzyme | Effect of Modafinil | Clinical Consequence | |---|---|---| | CYP3A4 / 3A5 | Inducer | Reduces plasma levels of CYP3A4 substrates | | CYP2C19 | Moderate inhibitor | Raises plasma levels of CYP2C19 substrates | | CYP2C9 | Weak inhibitor | Minor elevation of CYP2C9 substrate levels | | CYP1A2 | Possible weak inducer | Modest reduction of CYP1A2 substrates | | CYP2E1 | No significant effect | No relevant interaction with this pathway |

Acetaminophen as a CYP Substrate

Acetaminophen's primary clearance through glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation is not affected by modafinil. The approximately 5 to 15% that goes through CYP3A4 is the only enzymatically relevant slice. This is why the interaction is moderate rather than severe under typical conditions: the majority of acetaminophen clearance is unaffected.

However, Zhao et al. (2012) and related mechanistic pharmacology reviews consistently note that even a fractional increase in NAPQI output becomes clinically meaningful when glutathione stores are depleted or when acetaminophen doses approach 2,000 mg/day in vulnerable patients.

FDA Labeling: What Both Labels Actually Say

Provigil (Modafinil) FDA Label

The current Provigil prescribing information contains these relevant statements under Drug Interactions:

"Modafinil is a mild-to-moderate inducer of CYP3A4/5... Patients taking modafinil with medications metabolized by CYP3A4 may require dose adjustments of those medications."

The label does not name acetaminophen specifically. Acetaminophen is listed as a substrate of CYP3A4 in standard pharmacology references, making the general induction warning applicable.

The label also specifies: "In patients with severe hepatic impairment... The dose of PROVIGIL should be reduced to one-half of that recommended for patients with normal hepatic function."

Acetaminophen FDA Labeling

Over-the-counter acetaminophen labeling, reviewed by the FDA's Office of Nonprescription Drugs, carries a liver warning that states: "Severe liver damage may occur if you take more than 4 doses in 24 hours, which is the maximum daily amount... With other drugs containing acetaminophen... Or [with] 3 or more alcoholic drinks every day while using this product."

The FDA's 2011 action limiting prescription combination acetaminophen products to 325 mg per dose unit reflects agency-level concern about cumulative hepatic exposure. Co-administration of enzyme inducers like modafinil is not explicitly addressed in OTC labeling, which underscores the need for prescriber-level counseling rather than relying on package inserts alone.

Practical Dose Guidance for Concurrent Use

No regulatory body has published a specific dosing table for modafinil-acetaminophen combinations. The following guidance is synthesized from the FDA labels, LiverTox, and hepatotoxicity pharmacology literature:

For Healthy Adults (No Liver Disease, Minimal Alcohol Use)

Standard doses of both drugs are generally acceptable for short-term concurrent use (under 7 to 10 days). Acetaminophen should not exceed 3,000 mg/day as a conservative ceiling when modafinil is co-prescribed, given the directional NAPQI risk. This aligns with the recommendation from a 2020 review in Clinical Pharmacology and Therapeutics that suggested 3,000 mg/day as a safer upper limit even without a CYP inducer.

For Patients on Chronic Modafinil

Patients using modafinil daily for narcolepsy or shift-work sleep disorder (the two approved indications per the FDA label) should be counseled to keep acetaminophen at or below 2,000 mg/day and to consider scheduled dosing rather than ad hoc high-volume use.

For Patients With Hepatic Impairment

The combination should be used with caution and close monitoring. The Child-Pugh scoring system helps stratify hepatic reserve. In Child-Pugh B or C patients, both drugs require dose reductions independently, and their concurrent use should be discussed explicitly with a hepatologist.

Modafinil Approved Dosing for Reference

• Narcolepsy and obstructive sleep apnea: 200 mg once daily in the morning; may be increased to 400 mg/day.
• Shift-work sleep disorder: 200 mg taken approximately 1 hour before the start of the work shift.
• Pediatric use: Not approved for patients under 17 years.

Monitoring Parameters for Concurrent Use

Baseline Assessment

Before starting chronic concurrent therapy, order:

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
• Total bilirubin and alkaline phosphatase
• A brief alcohol use history using the AUDIT-C questionnaire
• Review of all acetaminophen-containing products (many combination cold and pain products include acetaminophen without prominent labeling)

During Therapy

For patients taking both drugs for more than 30 days, repeat LFTs at 3 months. A rise in ALT above 3 times the upper limit of normal warrants stopping the suspected offending agent and reassessing the combination. The DILI Network published in Gastroenterology (2015) documented that time to onset for CYP-mediated drug-induced liver injury typically falls between 5 and 90 days of exposure, which defines the monitoring window.

Symptom-Based Warning Signs

Patients should be instructed to report: right upper quadrant pain or tenderness, new-onset jaundice (yellowing of skin or eyes), dark urine, unusual fatigue, or loss of appetite. These symptoms require same-day clinical evaluation.

Patient Counseling Points

Clear patient education is where this interaction becomes actionable. A prescriber or clinical pharmacist should cover the following:

Total daily acetaminophen burden. Many patients do not realize that acetaminophen appears in dozens of combination products including NyQuil, Percocet (oxycodone/acetaminophen), Vicodin (hydrocodone/acetaminophen), and DayQuil. Total daily intake from all sources should stay under 3,000 mg when taking modafinil. Reading labels on every OTC product is not optional; it is necessary.

Alcohol avoidance or strict limits. Even moderate drinking (more than 1 drink per day for women, more than 2 for men per CDC alcohol guidelines) combined with modafinil's CYP3A4 induction and acetaminophen creates a three-way hepatic stress scenario.

Duration of exposure matters. A single dose of acetaminophen for a headache while on modafinil is clinically very different from 2,000 mg/day of acetaminophen for three months with concurrent daily modafinil. Patients tend to conflate these scenarios because the same two drugs are involved.

Do not adjust modafinil doses independently. Modafinil is Schedule IV under the Controlled Substances Act. Dose changes require a prescriber conversation. Patients should not reduce their modafinil dose in an attempt to "protect" their liver without consulting their provider, because sleep disorder management directly affects safety (drowsy driving, workplace accidents).

Alternative analgesics to consider. For patients with risk factors, a prescriber may recommend ibuprofen or naproxen instead of acetaminophen for short-term pain, acknowledging that NSAIDs carry their own contraindications (GI bleeding, renal function) that must be weighed individually.

Special Populations

Older Adults (Age 65 and Above)

Hepatic mass and blood flow decline with age, reducing both phase I and phase II metabolic capacity. The American Geriatrics Society Beers Criteria (2023) does not specifically flag modafinil-acetaminophen, but it recommends lower acetaminophen doses (maximum 3,000 mg/day) in older adults generally, and lower thresholds for LFT monitoring.

Patients With Narcolepsy or Idiopathic Hypersomnia

This group is most likely to be on long-term modafinil. Chronic sleep disorders themselves are associated with metabolic stress. A 2019 meta-analysis in Sleep Medicine Reviews found that patients with narcolepsy had higher rates of comorbid metabolic and hepatic conditions compared with population controls, suggesting this population deserves particularly careful monitoring of drug-induced hepatic load.

Patients Using Modafinil Off-Label for Cognitive Enhancement

Off-label use for attention, fatigue in cancer survivors, and cognitive function in multiple sclerosis is common. These patients may not be under close prescriber supervision. They should receive the same counseling about acetaminophen limits and liver monitoring as patients with approved indications.

What Current Evidence Cannot Tell Us

The honest answer is that no randomized pharmacokinetic study has directly measured NAPQI levels in humans taking both modafinil and therapeutic-dose acetaminophen simultaneously. The interaction is mechanistically grounded and biologically plausible, but the clinical magnitude has not been prospectively quantified. This gap means that risk estimates are extrapolated from:

• Modafinil's known CYP3A4 induction potency relative to reference inducers.
• Acetaminophen's known CYP3A4-dependent NAPQI fraction.
• Analog-induction studies with rifampin and carbamazepine.

A 2023 systematic review of acetaminophen drug interactions in Drug Safety identified CYP3A4 inducers as a class warranting closer surveillance for NAPQI-mediated hepatotoxicity, noting that the evidence base for individual inducers remains heterogeneous. Modafinil was not studied as a standalone comparator in that review, which itself represents a gap in the published literature.

Until prospective pharmacokinetic data exist, clinical management defaults to the conservative framework described above: standard doses for short periods are acceptable in healthy individuals; chronic co-use in at-risk patients requires a formal hepatic monitoring plan.